Catalyst
Slingshot members are tracking this event:
Aduro Biotech (ADRO) expects to submit an IND filing for Anti-PD1 cancer treatment in the first half of 2018
- Source Link:
- https://seekingalpha.com/filing/3351398
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADRO | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2019
Occurred Source:
https://www.globenewswire.com/news-release/2019/06/02/1862923/0/en/Aduro-Biotech-and-Novartis-Present-Results-from-Ongoing-Phase-1b-Study-of-STING-Agonist-ADU-S100-MIW815-in-Combination-with-Anti-PD-1-Monoclonal-Antibody-Spartalizumab-PDR001-in-Pa.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ind Filing, Anti-pd1, Cancer Treatment
